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Phthalate exposure is ubiquitous because of use
in plastics, cosmetics, and commercial prod-
ucts [Center for the Evaluation of Risks to
Human Reproduction (CERHR) 2000a,
2000b, 2000c]. Potential phthalate exposure
has been associated with respiratory symptoms
and disease in young children through the use
of questionnaires to assess surrogates for expo-
sure (e.g., building materials, synthetic bed-
ding; Jaakkola et al. 1999, 2000; Ponsonby
et al. 2003). Among Norwegian children,
bronchial obstruction was associated with
polyvinyl chloride (PVC) building materials in
the home (Jaakkola et al. 1999). In Finland,
Jaakkola et al. (2000) observed an increased
incidence of lower respiratory symptoms
among children in homes with plastic wall
materials. Australian infants using synthetic
bedding materials had higher odds of wheeze
at 7 years of age than did other children
(Ponsonby et al. 2003). No data on phthalates
and respiratory outcomes are available for
adults, although beauticians, who are thought
to have higher phthalate exposure, have higher
rates of respiratory symptoms (Hollund 2001).
Until recently, there was no direct way to
measure phthalate exposure in environmen-
tally exposed individuals. A urinary biomarker
is now available to assess specific phthalate
monoesters (Blount et al. 2000a). This bio-
marker reﬂects recent exposure and has been
demonstrated to be reliable from one day to
the next (Hoppin et al. 2002). To explore the
respiratory impact of phthalates in adults, we
used urinary levels of phthalate monoesters
and linked these to spirometry data collected
the same day.
Materials and Methods
We used urinary phthalate data from the 289
participants in the Third National Health and
Nutrition Examination Survey (NHANES III)
whose urine samples were randomly selected
for phthalate analysis (Blount et al. 2000b).
Urinary phthalate measures were available only
for this small subset of NHANES III parti-
cipants. Participants in this subgroup were
enrolled between 1988 and 1994 and ranged in
age from 20 to 60 years. The 240 individuals
(140 females, 100 males) with urine samples
and complete data on pulmonary function and
medical and smoking history were included in
this analysis (Table 1). African-American and
white subjects were included in this analysis;
individuals of other races were excluded
because there were few with phthalate meas-
ures. Seven phthalate monoesters were meas-
ured in spot urine samples using high-pressure
liquid chromatography mass spectrometry
(Blount et al. 2000b). The four phthalates
[monobutyl phthalate (MBP), monobenzyl
phthalate (MBzP), monoethyl phthalate
(MEP), and monoethylhexyl phthalate
(MEHP)] detected in most of the samples were
included in this analysis. The remaining three
phthalates (monocyclohexyl phthalate, mono-
isononylphthalate, and mono-octyl-phthalate)
were detected in < 25% of the sample and were
not included in this analysis.
Pulmonary function measures analyzed
were forced vital capacity (FVC), forced expi-
ratory volume at 1 sec (FEV1), peak expiratory
flow (PEF), and maximum mid-expiratory
ﬂow (MMEF). We conducted analyses on the
FEV1:FVC ratio as well, but the results were
similar to those for FEV1 and FVC and are
not reported here. Spirometry was conducted
according to the 1987 American Thoracic
Society recommendations [National Center
for Health Statistics (NCHS) 2001]. Data
were also available on respiratory symptoms,
but because of the small sample size and the
potential lack of temporal relevance, they were
not included in this analysis.
Linear regression analysis was used to
evaluate the association between phthalates
and pulmonary function parameters. Separate
regression models were used for females and
males. Regression models were adjusted for
age, age squared, standing height, body mass
index, cumulative smoking (pack-years), cur-
rent smoking (cigarettes per day), and race.
Smoking was parameterized in several ways.
Variables for both cumulative smoking and
current smoking were included to adjust for
both the long-term effect of smoking on pul-
monary function and the positive correlation
between cigarettes per day and MBP. Phthalate
levels were adjusted for creatinine concentra-
tion and log transformed for linear regression
analysis. Four individuals (2 men, 2 women)
were missing information on MEP, and 18
individuals (3 men, 15 women) were missing
information on MEHP. For individuals with
missing phthalate information, a value of half
the analytical detection limit was assigned for
MEP (0.5 ng/mL), and the lowest reported
value was used for MEHP (0.04 ng/mL)
because this value was lower than half the ana-
lytical detection limit (0.6 ng/mL). Regression
coefficients were reported for the gender-
speciﬁc interquartile range for each phthalate.
Results
This subsample of 240 NHANES III partici-
pants was similar to the main NHANES III
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Exposure to phthalates is widespread because of their use in plastics, cosmetics, and other consumer
products. Phthalate exposure has been associated with adverse respiratory outcomes in children.
With urinary phthalate measures, we assessed the association between phthalate exposure and four
pulmonary function parameters [forced vital capacity (FVC), forced expiratory volume at 1 sec
(FEV1), peak expiratory ﬂow (PEF), and maximum mid-expiratory ﬂow] among the 240 adult Third
National Health and Nutrition Examination Survey (NHANES III) participants with urinary phtha-
late data. Linear regression models controlled for race, age, age squared, standing height, body mass
index, cumulative smoking, and current smoking. Monobutyl phthalate (MBP) was signiﬁcantly
associated with decrements in three measures of pulmonary function (FVC, FEV1, PEF) in males but
not in females. For a change from the 25th to the 75th percentile in MBP level among men, FEV1
decreased 112 mL (SE = 51, p = 0.03). Monoethyl phthalate (MEP) was associated with lower FVC
and FEV1 values in men. Monoethylhexyl phthalate (MEHP), the metabolite of the plasticizer com-
monly used in medical tubing, was not adversely associated with any of the pulmonary function
parameters evaluated. Our results suggest that MBP and MEP, but not MEHP, may inﬂuence pul-
monary function among adult males. Key words: monobutyl phthalate, pulmonary function, urine
samples. Environ Health Perspect 112:571–574 (2004). doi:10.1289/ehp.6564 available via
http://dx.doi.org/ [Online 15 January 2004]population on demographic and smoking
status variables with the exceptions of a slightly
higher percentage of women (58 vs. 53%) and
slightly lower percentage of never smokers
(47 vs. 50%; Table 1). The pulmonary func-
tion and urinary phthalate values for this sub-
sample are presented in Table 2. MBP levels
in urine were significantly associated with
decrements in pulmonary function in males
but not in females (Table 3). Among males, a
change from the 25th percentile to the 75th
percentile in MBP concentration was associ-
ated with the following changes in pulmonary
function: –131 mL (SE = 63, p = 0.04) for
FVC, –112 mL (SE = 51, p = 0.04) for FEV1,
and –367 mL/sec (SE = 181, p = 0.05) for
PEF. MEP concentration was inversely associ-
ated with FVC and FEV1 among males; these
results were no longer statistically signiﬁcant
when the two men with nondetectable levels of
phthalates were excluded. When subjects with
self-reported asthma and bronchitis were
excluded, the associations between MBP and
MEP and pulmonary function parameters were
virtually unchanged. When we limited analysis
to the 37 male never smokers, MBP was sig-
niﬁcantly associated with decreased FVC with
a regression coefficient of –190 (SE = 78,
p = 0.02). Other point estimates for nonsmok-
ing men were essentially unchanged from the
whole sample. Among the 76 nonsmoking
women, MEHP, but not other phthalates,
was positively associated with FEV1 and
MMEF. When the analysis was limited to
individuals with detectable levels of MEHP,
the association between MEHP and FEV1
was no longer signiﬁcant. When we ran mod-
els using the phthalate levels unadjusted for
creatinine concentration, we observed essen-
tially the same results, with the exception that
the association between MBP and PEF was
no longer statistically signiﬁcant (p = 0.11).
Discussion
We observed respiratory decrements associated
with urinary measures of phthalates in men but
not in women. Previous pulmonary function
analyses of the NHANES III data identified
responses in women, but not in men, associated
with serum cotinine measures of environmental
tobacco smoke exposure (Eisner 2002). The
magnitudes of the associations observed with
MBP and MEP among men are similar to
those observed for environmental tobacco
smoke among women.
Although common in analyses of respira-
tory health effects, we were unable to limit our
analysis to never smokers because of the small
sample size. Occupational studies have assessed
the effects of respiratory toxicants among all
workers without limiting to nonsmokers and
have controlled for smoking in their models
(Beach et al. 2001; Gardiner et al. 2001;
Ulvestad et al. 2000). We adopted this strategy
and were able to adjust for both current and
lifetime smoking history in our models and to
conduct an analysis limited to the small num-
ber of never smokers in our sample. The results
were essentially the same with the exception of
a positive association between MEHP and
FEV1 and MMEF in nonsmoking women.
Determining whether this is a chance ﬁnding
will have to wait until there are larger sample
sizes by which to evaluate this question.
Other analyses of respiratory health effects
have used surrogates to assess phthalate expo-
sure. Ponsonby et al. (2003) used information
on synthetic bedding materials as an indicator
of potential phthalate exposure. In studies by
Jaakkola et al. (1999, 2000) in Norway and
Finland, the questionnaire data on amount of
plastic in the home was used as a surrogate for
phthalate exposure; the authors assumed that
this phthalate was mainly diethylhexyl phtha-
late (DEHP). Work by Oie et al. (1997) in
Norway suggests that even though DEHP has
a low vapor pressure, it is commonly found in
indoor air on suspended particulate in homes
and thus represents a potential route of respi-
ratory exposure. In Boston, phthalates have
been detected in the dust and air in a small
study of residential and office settings, with
high-molecular-weight phthalates (e.g.,
DEHP) found in higher concentration in
Article | Hoppin et al.
572 VOLUME 112 | NUMBER 5 | April 2004 • Environmental Health Perspectives
Table 1. Characteristics of the 240 NHANES III participants with urinary phthalate data, 1988–1994, compared
with the NHANES III cohort.
Participants with phthalate data (%) NHANES participants 20–60 years of age (%)
Characteristic Males (n = 100) Females (n = 140) Males (n = 5,719) Females (n = 6,501)
Race
Black 32 34 31 34
White 68 66 65 63
Smoking history
Never 37 54 39 60
Current 46 29 37 26
Past 17 17 24 15
Medical history
Asthma 3 6 6 7
Bronchitis 1 7 3 6
Age at interview (years)
20–29 24 32 31 30
30–39 28 22 28 30
40–49 31 29 22 22
50–60 17 17 19 18
Body mass index (kg/m2)
< 25 39 36 41 41
25–30 31 27 39 29
> 30 30 37 20 30
Table 2. Pulmonary function data and urinary phthalate values for the 240 NHANES III participants with urinary phthalate data, 1988–1994.
Males (n = 100) Females (n = 140)
Measured values Mean ± SD Minimum Maximum Mean ± SD Minimum Maximum
Pulmonary function measures
FVC (mL) 4,808 ± 808 2,430 7,082 3,472 ± 676 1,527 5,314
FEV1 (mL) 3,797 ± 678 2,179 5,353 2,822 ± 617 1,144 4,385
PEF (mL/sec) 9,143 ± 1693 4,564 13,210 6,702 ± 1,402 2,584 9,946
MMEF (mL/sec) 3,628 ± 1330 615 6,957 2,969 ± 1,147 419 6,185
Phthalate measures (ng phthalate/g creatinine)a
MBP 30 (2.5) 1.6 962 45 (3.1) 4.7 2,763
MBzP 17 (2.5) 2.1 544 23 (2.4) 2.3 189
MEP 240 (5.4) 0.2 6,786 321 (4.2) 0.5 4,539
MEHP 2 (3.2) 0.05 49 2 (5.0) 0.02 192
Phthalate measures (unadjusted for creatinine, ng phthalate/mL urine)
MBP 40 ± 2.9 2.2 1,121 43 ± 3.9 4.0 4,665
MBzP 22 ± 3.0 1.84 1,015 22 ± 2.9 1.7 338
MEP 323 ± 6.4 0.50 16,150 307 ± 4.9 0.5 11,192
MEHP 3.3 ± 3.8 0.04 67 2.0 ± 5.8 0.04 66
aGeometric means and geometric standard deviations reported for phthalate measures.dust and low-molecular-weight phthalates
(e.g., dibutyl phthalate) found in higher con-
centrations in air (Rudel et al. 2001, 2003).
Although these data indicate that phthalates
are found in indoor environments, whether
these are associated with plastic materials in
the home has not yet been determined.
Hairdressers have higher rates of respira-
tory symptoms (Hollund 2001; Iwatsubo et al.
2003) and are likely to have higher phthalate
exposures due to use of dibutyl phthalates and
diethyl phthalates in cosmetics and fragrances.
In a recent study, Iwatsubo et al. (2003)
reported that hairdressing apprentices had
greater reduction in FVC, FEV1, and MMEF
over time compared with office apprentices.
Although the hairdressers were predominantly
female (85%), the pulmonary function results
were similar to those observed among the men
in our study for MBP and MEP. Until phtha-
late measurements are collected among hair-
dressers and beauticians, we will be unable to
evaluate whether MBP and MEP contribute to
the observed respiratory health effects among
hairdressers.
Of current concern are individuals who are
receiving pulmonary therapies through PVC
tubing that may contain DEHP, the phthalate
most commonly found in medical tubing
(Latini and Avery 1999; Tickner et al. 2001).
We did not observe an adverse association
between MEHP and any of the pulmonary
function parameters evaluated.
Identifying sources of phthalates that con-
tribute to urinary levels in the general popu-
lation is an ongoing research effort. Until
recently there were no population data on
urinary phthalate levels, and to date there are
no published data that indicate sources of
exposure associated with biomarkers. Women
have been reported to have higher urinary lev-
els than men [Blount et al. 2000b; Centers for
Disease Control and Prevention (CDC) 2003],
and socioeconomic status and education
appear to be weakly associated with phthalate
levels (Koo et al. 2002). In this analysis, we
observed a positive association between current
smoking and MBP levels and thus controlled
for this in our models. Whether smoking is
directly related to phthalate exposure is not
known. The urinary phthalate levels from the
NHANES III sample collected from 1988
through 1994 are generally higher than the
levels measured in the recent NHANES
1999–2000 (CDC 2003). This may suggest
that phthalate levels are decreasing in the U.S.
population, although the concentrations are
still at measurable levels and the distribution
continues to span three orders of magnitude.
We used a biologic measure to assess
phthalate exposure. Urinary phthalate meas-
ures have a short biologic half-life but are
reproducible from one day to the next
(Hoppin et al. 2002); long-term reproducibil-
ity has not been evaluated. Pulmonary func-
tion tests generally represent long-term
changes in lung function, although work shift
changes in FEV1 and other pulmonary func-
tion tests have been demonstrated (Wang
et al. 2003). Whether our measure of phtha-
lates was indicative of long-term exposure, and
thus long-term change in pulmonary function,
or indicative only of recent exposure, and thus
short-term changes in pulmonary function, we
cannot determine from our cross-sectional
analysis.
Because biologic markers integrate over all
exposure routes, we cannot know whether the
observed differences in males and females rep-
resent different underlying biology or different
patterns of exposure. Women have higher
levels of MBP on average (Blount et al. 2000b;
CDC 2003); however, women may have
greater exposure via the dermal route whereas
men may have greater exposure via inhalation.
Currently, there are no measurement data
available to explore the impact of phthalate
exposure route on urinary phthalate levels or
health outcomes. Previous work assessing
phthalate exposure and respiratory function in
children relied on surveys of plastic materials in
the home (Jaakkola et al. 1999, 2000) and use
of synthetic bedding (Ponsonby et al. 2003).
These measures may be more likely to capture
inhalation exposure via respiratory routes (e.g.,
off-gassing from phthalate containing materials
and suspended particulates) than exposure via
dermal routes (Oie et al. 1997). Although our
sample may be underpowered to assess the role
of all phthalates on pulmonary function, these
exploratory results suggest that MBP and MEP
may be associated with adverse pulmonary
function among adult men.
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